{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:46:46Z","timestamp":1791179206940,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ejca.2012.08.017","type":"journal-article","created":{"date-parts":[[2012,9,13]],"date-time":"2012-09-13T16:01:59Z","timestamp":1347552119000},"page":"386-394","source":"Crossref","is-referenced-by-count":114,"title":["Panobinostat activity in both bexarotene-exposed and -na\u00efve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial"],"prefix":"10.1016","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct00425555","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Poulalhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ortiz Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Grazia Bernengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Squier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Marshood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2012.08.017_b0005","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO\u2013EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2012.08.017_b0010","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2133.2010.10143.x","article-title":"Primary cutaneous lymphoma: two-decade comparison in a population of 263 cases from a Swiss tertiary referral centre","volume":"164","author":"Jenni","year":"2011","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.ejca.2012.08.017_b0015","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/blood-2010-09-305128","article-title":"High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS\/RAF\/MEK signaling cascade","volume":"117","author":"Kiessling","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.08.017_b0175","doi-asserted-by":"crossref","unstructured":"Dummer R, Dreyling M; ESMO Guidelines Working Group. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 (Suppl. 2):ii72\u20136.","DOI":"10.1093\/annonc\/mdn095"},{"issue":"5","key":"10.1016\/j.ejca.2012.08.017_b0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1529-8019.2006.00083.x","article-title":"Treatment of cutaneous T-cell lymphoma with retinoids","volume":"19","author":"Zhang","year":"2006","journal-title":"Dermatol Ther"},{"issue":"9","key":"10.1016\/j.ejca.2012.08.017_b0030","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II\u2013III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2012.08.017_b0035","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2012.08.017_b0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.ejca.2012.08.017_b0045","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/82.3.208","article-title":"Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kaplan","year":"1990","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ejca.2012.08.017_b0050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2012.08.017_b0055","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2012.08.017_b0060","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2012.08.017_b0065","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","article-title":"Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients","volume":"34","author":"Zackheim","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2012.08.017_b0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"22","key":"10.1016\/j.ejca.2012.08.017_b0075","first-page":"919","article-title":"Pralatrexate is active in cutaneous T-cell lymphoma (CTCL): results of a multicenter, dose-finding trial","volume":"114","author":"Horwitz","year":"2009","journal-title":"ASH Annu Meet Abstr"},{"issue":"27","key":"10.1016\/j.ejca.2012.08.017_b0080","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2012.08.017_b0085","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2012.08.017_b0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ejca.2012.08.017_b0095","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ejca.2012.08.017_b0100","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.ejca.2012.08.017_b0105","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2012.08.017_b0110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.ejca.2012.08.017_b0115","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2217\/fon.09.36","article-title":"Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors","volume":"5","author":"Prince","year":"2009","journal-title":"Future Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2012.08.017_b0120","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2012.08.017_b0125","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2012.08.017_b0130","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2012.08.017_b0135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/107327480100800213","article-title":"Infectious complications of cutaneous T-cell lymphoma","volume":"8","author":"Tsambiras","year":"2001","journal-title":"Cancer Control"},{"issue":"10","key":"10.1016\/j.ejca.2012.08.017_b0140","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","article-title":"Infections complicating mycosis fungoides and Sezary syndrome","volume":"267","author":"Axelrod","year":"1992","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ejca.2012.08.017_b0145","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1365-4362.1997.00329.x","article-title":"Cutaneous T-cell lymphoma","volume":"36","author":"Dalton","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ejca.2012.08.017_b0150","unstructured":"Duvic M, Dummer R, Hirawat S, et al. Definition of progressive disease impacts the outcome in cutaneous T-cell lymphoma (CTCL) trials. In: International society for cutaneous lymphomas annual meeting, 2009."},{"issue":"2","key":"10.1016\/j.ejca.2012.08.017_b0155","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2010.262","article-title":"Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes","volume":"25","author":"Giver","year":"2011","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.ejca.2012.08.017_b0160","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biological processes that mediate histone deacetylase inhibitor-induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.ejca.2012.08.017_b0165","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin\u2019s lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200679X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200679X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T21:03:36Z","timestamp":1562187816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491200679X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S095980491200679X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.08.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}